Seraseq® Postpartum 22q11 Male cfDNA

The Seraseq Antepartum and Postpartum 22q11 Male cfDNA products are intended as reference materials for non-invasive prenatal testing (NIPT) of the 22q11 fetal microdeletion in pregnant patients via cell-free DNA (cfDNA) analysis.

Those products are derived from a naturally-occurring mixture of matched (or related) maternal and fetal circulating cell-free DNA in a pregnant donor blood sample whose male fetus has been diagnosed with a 22q11 microdeletion (DiGeorge Syndrome).

• Seraseq Antepartum 22q11 Male cfDNA is derived from a pregnant patient blood sample carrying a male fetus with confirmed 22q11 microdeletion.
• Seraseq Postpartum 22q11 Male cfDNA is derived from the same patient blood sample collected after birth. 

Supplied as purified cfDNA in 0.1X TE buffer, the Postpartum 22q11 Male cfDNA can be used as a 22q11 reference material in assay development, validation, verification, analysis and routine monitoring of test performance as well as troubleshooting and training. It can be either used as supplied or used to dilute the matching Seraseq Antepartum 22q11 Male cfDNA (cat# 0720-1102), in order to decrease the estimated fetal fraction of the sample and perform limit of detection (LoD) studies.

• Derived from a postnatal pregnant donor’s blood whose male fetus has been identified with a 22q11 microdeletion (DiGeorge Syndrome)

• Matched (or related) maternal-fetal material compatible with a broad range of NIPT assay methods

• Proprietary method preserves native cfDNA characteristics such as size profile of ~170 bp, SNP content and natural maternal-fetal size difference

• Supplied as purified cfDNA in 0.1X TE buffer which can be added during the library preparation step

• Long shelf-life and lot-to-lot consistency with high quality materials manufactured in GMP-compliant and ISO 13485-certified facilities under strict quality checks